Lokker N A, Zenke G, Strittmatter U, Fagg B, Movva N R
Preclinical Research, Sandoz Pharma Ltd, Basle, Switzerland.
EMBO J. 1991 Aug;10(8):2125-31. doi: 10.1002/j.1460-2075.1991.tb07746.x.
A structure-activity relationship study of human interleukin-3 (huIL-3) was performed by functional analysis of huIL-3 deletion and substitution variants combined with epitope mapping of huIL-3 specific neutralizing monoclonal antibodies (mAb). Analysis of the huIL-3 variants was accomplished by defining their capacity to compete with wild-type huIL-3 for binding to the huIL-3 receptor and to induce the proliferation of the huIL-3 dependent cell line M-O7. HuIL-3 variants with either 14 amino acids (aa) deleted from the N-terminus or eight aa from the C-terminus retained full biological activity in vitro. An huIL-3 variant, with 18 N-terminal aa deleted, exhibited a greater than 7-fold reduced receptor binding capacity and proliferative activity. No biological activity could be detected with a variant where 22 C-terminal aa have been deleted. Neutralizing mAb recognizing presumed discontinuous epitopes failed to interact with the latter deletion variant indicating a possible location of their epitopes within the C-terminal region. Computer-aided structure prediction and sequence homology analysis of this region indicated the presence of an amphiphilic alpha-helix with highly conserved residues like Lys110 and Leu111. Substitution of Lys110 with either Glu or Ala resulted in variants with a 10-fold reduced activity in the receptor binding assay and the proliferation assay. Further variants, where Leu111 was substituted by Pro or Met, were totally inactive in these assays. Analysis of the binding of the two neutralizing mAb to these substitution variants showed that they did not bind to either of the Leu111 variants suggesting that Leu111 is part of an active site. Based on our results, a possible model for the structure of the huIL-3 molecule can be constructed with two active sites in close proximity.
通过对人白细胞介素-3(huIL-3)缺失和替代变体进行功能分析,并结合huIL-3特异性中和单克隆抗体(mAb)的表位定位,开展了huIL-3的构效关系研究。通过确定huIL-3变体与野生型huIL-3竞争结合huIL-3受体以及诱导huIL-3依赖细胞系M-O7增殖的能力,完成了对huIL-3变体的分析。从N端缺失14个氨基酸(aa)或从C端缺失8个aa的huIL-3变体在体外保留了全部生物学活性。一个从N端缺失18个aa的huIL-3变体,其受体结合能力和增殖活性降低了7倍以上。删除22个C端aa的变体未检测到生物学活性。识别假定不连续表位的中和mAb未能与后一种缺失变体相互作用,表明其表位可能位于C端区域内。对该区域进行计算机辅助结构预测和序列同源性分析表明,存在一个两亲性α-螺旋,具有高度保守的残基,如Lys110和Leu111。用Glu或Ala替代Lys110导致变体在受体结合试验和增殖试验中的活性降低了10倍。进一步的变体,其中Leu111被Pro或Met替代,在这些试验中完全无活性。分析两种中和mAb与这些替代变体的结合情况表明,它们不与任何一种Leu111变体结合,这表明Leu111是活性位点的一部分。根据我们的结果,可以构建一个huIL-3分子结构的可能模型,其中两个活性位点紧密相邻。